Previous close | 49.75 |
Open | 49.75 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 1,040.00 |
Expiry date | 2025-01-17 |
Day's range | 49.75 - 49.75 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Insightful Analysis of Regeneron's Financials and Strategic Positioning
Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.